Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
Client Groups
Venture Capital & Private Equity Investors
Private capital drives the translation of new learnings in basic science to the development of products that meet medical needs. Notwithstanding the proliferation of “industry standard” venture financing documents, crafting the financial and governance terms of a financing to align the interests of scientific founders and investors remains an art.
Overview
Faber has deep experience counseling a significant number of the most prominent U.S.-based life science venture capital and private equity firms. Our experience is broad, and we routinely guide investor clients on seed and later-stage financing transactions, new company incubation activities, and strategic transactions and exits impacting portfolio companies.
In each case, the Faber deal team brings to bear its deep experience serving as outside general or transactional counsel to its discovery and clinical stage therapeutic and other life science companies.
We have strong relationships with the investor groups that focus on the biotech and life science verticals and have advised many of them on their own transactions.
A deeper understanding
We understand our venture capital and private equity clients’ priorities and needs – the value drivers and vulnerabilities that inform valuation and execution risk - because we so deeply understand the priorities and needs of their prospective portfolio companies.
This knowledge positions the Faber team to efficiently and thoughtfully structure investments, advise on key governance and fiduciary considerations, and, perhaps most critically, diligence the truly material risks for the archetypal prospective portfolio company: its foundational in-licenses from academia, its partnering and collaboration relationships, and its clinical contracting and supply chain agreements.
